Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

NCT06099067

CompletedN/A

Sponsor: AstraZeneca

Conditions: Type 2 Diabetes Mellitus

Interventions: Canagliflozin, DPP4 inhibitor, Liraglutide, Saxagliptin, 2nd generation Sulfonylurea

Countries: Sweden

Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
The Eligibility Criteria for CANVAS, LEADER and SAVOR-TIMI are replicated

Please see the Criteria for each under:

* CANVAS: https://clinicaltrials.gov/ct2/show/NCT03936010
* LEADER: https://clinicaltrials.gov/ct2/show/NCT03936049
* SAVOR-TIMI: https://clinicaltrials.gov/ct2/show/NCT03936023
Locations (1)
  • Gothenburg, Sweden